Using AI in Drug Discovery
This panel will explore emerging technologies, examine machine learning and data in drug research, and uncover how they work in combination to support medical breakthroughs. Uncover how to make it from the discovery stage to trials, while speeding up the process in drug development.
• Charles Fisher – CEO & Founder, Unlearn.AI
Accelerating Industry Growth with Pure Tech & Pure Science: Building on San Francisco’s Tech Identity to Further Life Sciences & Healthcare
San Francisco is a world leader in innovation, and this panel will explore what makes the area unique as a life sciences hub. We will follow the local growth of health technologies, the unique mix of pure science with pure tech, and adjustments made to address the current global challenges. We will cover how companies using big data manage distancing requirements, approaches to establishing an effective and diverse tech and life science work environment/taskforce/work culture, and how proximity to the Bay Area strengthens the industry and accelerates growth.
• Brandon Allgood – SVP of Data & AI, Integral Health
What’s Next: Investment, Partnerships & Pushing Life Sciences Forward
San Francisco holds a significant amount of capital – but where are there gaps in the market? How are investor, entrepreneur, and partnerships formed, and how can you get an investor to follow your work from the beginning? With the talent in the Bay Area, what does the future hold for bringing more therapies to market? And as the COVID-19 pandemic continues, what role will the life sciences tech landscape look like? Does it change investment models, speed up drugs to market, or create competition?
• Michael Henderson – CBO, BridgeBio
• The Bay Area and Beyond: Biocom Talks Innovation and COVID-19